Alejandro Díaz Holguín
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alejandro Díaz Holguín has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Jens Carlsson
Science for Life Laboratory, Department of Cell and Molecular Biology, Uppsala University, Uppsala, Sweden
3 shared publications - Israel Cabeza de Vaca
Science for Life Laboratory, Department of Cell and Molecular Biology, Uppsala University, Uppsala, Sweden
2 shared publications - Nour Aldin Kahlous
Science for Life Laboratory, Department of Cell and Molecular Biology, Uppsala University, BMC Box 596., SE-751 24 Uppsala, Sweden
2 shared publications Aikaterini Motso
Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
1 shared publicationAndrea Sturchio
Neuro Svenningsson, Department of Clinical Neuroscience, Karolinska Institute, SE-171 76 Stockholm, Sweden
1 shared publication- Annika Lindqvist
Department of Pharmacy, SciLifeLab Drug Discovery and Development Platform, Uppsala University, Box 580, SE-751 23 Uppsala, Sweden
1 shared publication
Latest Publications
- Open Access
- 4 May 2026
- Published by American Chemical Society (ACS) in Journal of Chemical Information and Modeling
- Vol. 66 (10) , 6045-6056
Improving AlphaFold2 Performance in Virtual Screens Targeting GPCRs by Enhancing Binding-Site Conformational Sampling
Artificial intelligence has transformed protein structure prediction, with AlphaFold2 (AF2) generating models with near-experimental accuracy. However, as AF2 was trained to generate a single structural model, this method does not capture the conformational flexibility of proteins, limiting its utility for structure-based drug design. Here, we explore strategies to generate diverse ensembles of binding-site models suitable for structure-based virtual screening against G protein-coupled receptors (GPCRs), a major class of drug targets. Our AFsample2T approach uses multiple sequence alignment column masking in the receptor binding site to reduce coevolutionary signals, leading to greater structural heterogeneity in the generated models. We demonstrate that ensembles of AFsample2T models capture multiple relevant binding-site conformations and reproduce experimentally observed conformational variability. Evaluation of AF2-based models in structure-based virtual screening using docking of actives and decoys shows that considering ensembles of diverse binding-site models substantially improves ligand enrichment. Our results provide guidelines for using AF2-based models in structure-based ligand discovery for GPCRs, and the AFsample2T approach can readily be applied to other protein classes.
- 4 May 2026
- Published by American Chemical Society (ACS) in Journal of Chemical Information and Modeling
- Vol. 66 (10) , 6045-6056
Open AccessImproving AlphaFold2 Performance in Virtual Screens Targeting GPCRs by Enhancing Binding-Site Conformational Sampling
Artificial intelligence has transformed protein structure prediction, with AlphaFold2 (AF2) generating models with near-experimental accuracy. However, as AF2 was trained to generate a single structural model, this method does not capture the conformational flexibility of proteins, limiting its utility for structure-based drug design. Here, we explore strategies to generate diverse ensembles of binding-site models suitable for structure-based virtual screening against G protein-coupled receptors (GPCRs), a major class of drug targets. Our AFsample2T approach uses multiple sequence alignment column masking in the receptor binding site to reduce coevolutionary signals, leading to greater structural heterogeneity in the generated models. We demonstrate that ensembles of AFsample2T models capture multiple relevant binding-site conformations and reproduce experimentally observed conformational variability. Evaluation of AF2-based models in structure-based virtual screening using docking of actives and decoys shows that considering ensembles of diverse binding-site models substantially improves ligand enrichment. Our results provide guidelines for using AF2-based models in structure-based ligand discovery for GPCRs, and the AFsample2T approach can readily be applied to other protein classes.
- Open Access
- 23 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Molecular mechanisms of native ligand selectivity in catecholamine G protein-coupled receptors
Activation of G protein-coupled receptors (GPCRs) by extracellular ligands is crucial for cellular communication and modulates numerous physiological processes. Despite sharing highly similar orthosteric binding sites, catecholamine GPCRs exhibit exquisite selectivity for their native agonists, even among nearly identical chemical messengers. However, the molecular basis and evolution of receptor selectivity remain poorly understood. To elucidate the structural mechanisms of GPCR selectivity, we focus on the prototypical human β 2 -adrenergic and D 1 dopaminergic receptors, which are important drug targets and respond to the catecholamines adrenaline/noradrenaline and dopamine, respectively. Guided by structural and sequence data, we identify a small set of residues responsible for ligand selectivity. By exchanging residues at four positions in the β-adrenergic receptors and seven in the D 1 -like dopaminergic receptors, we swap the pharmacological profiles of the two subfamilies. Unexpectedly, the switch in selectivity not only involves residues interacting with the ligand, but is also controlled by regions outside the orthosteric binding site. Cryo-electron microscopy structures and computational models of the mutant receptors identify distinct molecular mechanisms contributing to selectivity in a concerted manner. Our findings provide insights into GPCR evolution and highlight strategies for protein engineering and drug design.
- 23 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessMolecular mechanisms of native ligand selectivity in catecholamine G protein-coupled receptors
Activation of G protein-coupled receptors (GPCRs) by extracellular ligands is crucial for cellular communication and modulates numerous physiological processes. Despite sharing highly similar orthosteric binding sites, catecholamine GPCRs exhibit exquisite selectivity for their native agonists, even among nearly identical chemical messengers. However, the molecular basis and evolution of receptor selectivity remain poorly understood. To elucidate the structural mechanisms of GPCR selectivity, we focus on the prototypical human β 2 -adrenergic and D 1 dopaminergic receptors, which are important drug targets and respond to the catecholamines adrenaline/noradrenaline and dopamine, respectively. Guided by structural and sequence data, we identify a small set of residues responsible for ligand selectivity. By exchanging residues at four positions in the β-adrenergic receptors and seven in the D 1 -like dopaminergic receptors, we swap the pharmacological profiles of the two subfamilies. Unexpectedly, the switch in selectivity not only involves residues interacting with the ligand, but is also controlled by regions outside the orthosteric binding site. Cryo-electron microscopy structures and computational models of the mutant receptors identify distinct molecular mechanisms contributing to selectivity in a concerted manner. Our findings provide insights into GPCR evolution and highlight strategies for protein engineering and drug design.
- Open Access
- 2 December 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Doing More with Less: Accurate and Scalable Ligand Free Energy Calculations by Focusing on the Binding Site
Predicting how chemical modifications affect drug binding is central to rational drug design. Free Energy Perturbation (FEP) calculations provide accurate estimates of these binding affinity changes, but existing methods often require substantial computational resources and expert knowledge. Here we present QligFEP v2.1.0, an automated open-source platform for calculating relative binding free energies using spherical boundary conditions (SBC), which dramatically reduces computational cost by confining simulations to a focused region around the binding site. QligFEP features a configurable restraint algorithm that automatically handles diverse chemical transformations, streamlined setup procedures, and enhanced analysis tools. We validated the method using industry benchmarks comprising 16 protein targets and 639 ligand transformations. Statistical analysis demonstrates that QligFEP achieves comparable accuracy to established commercial and open-source alternatives, while requiring only a fraction of the computational resources. The perturbation protocol simulates ~6250 atoms per perturbation leg and completes transformation replicates in under 2 hours on standard computational clusters, which is substantially faster than traditional full-system simulations, and currently would cost less than $1 on current AWS spot instances. The combination of accuracy, automation, and computational efficiency positions QligFEP as a practical solution for accelerating compound optimization in drug discovery, making rigorous binding affinity predictions accessible for large scale applications and to research groups with limited computational infrastructure.
- 2 December 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessDoing More with Less: Accurate and Scalable Ligand Free Energy Calculations by Focusing on the Binding Site
Predicting how chemical modifications affect drug binding is central to rational drug design. Free Energy Perturbation (FEP) calculations provide accurate estimates of these binding affinity changes, but existing methods often require substantial computational resources and expert knowledge. Here we present QligFEP v2.1.0, an automated open-source platform for calculating relative binding free energies using spherical boundary conditions (SBC), which dramatically reduces computational cost by confining simulations to a focused region around the binding site. QligFEP features a configurable restraint algorithm that automatically handles diverse chemical transformations, streamlined setup procedures, and enhanced analysis tools. We validated the method using industry benchmarks comprising 16 protein targets and 639 ligand transformations. Statistical analysis demonstrates that QligFEP achieves comparable accuracy to established commercial and open-source alternatives, while requiring only a fraction of the computational resources. The perturbation protocol simulates ~6250 atoms per perturbation leg and completes transformation replicates in under 2 hours on standard computational clusters, which is substantially faster than traditional full-system simulations, and currently would cost less than $1 on current AWS spot instances. The combination of accuracy, automation, and computational efficiency positions QligFEP as a practical solution for accelerating compound optimization in drug discovery, making rigorous binding affinity predictions accessible for large scale applications and to research groups with limited computational infrastructure.
- Top Cited PapersOpen Access
- 9 August 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (32) , eadn1524
AlphaFold accelerated discovery of psychotropic agonists targeting the trace amine–associated receptor 1
Artificial intelligence is revolutionizing protein structure prediction, providing unprecedented opportunities for drug design. To assess the potential impact on ligand discovery, we compared virtual screens using protein structures generated by the AlphaFold machine learning method and traditional homology modeling. More than 16 million compounds were docked to models of the trace amine–associated receptor 1 (TAAR1), a G protein–coupled receptor of unknown structure and target for treating neuropsychiatric disorders. Sets of 30 and 32 highly ranked compounds from the AlphaFold and homology model screens, respectively, were experimentally evaluated. Of these, 25 were TAAR1 agonists with potencies ranging from 12 to 0.03 μM. The AlphaFold screen yielded a more than twofold higher hit rate (60%) than the homology model and discovered the most potent agonists. A TAAR1 agonist with a promising selectivity profile and drug-like properties showed physiological and antipsychotic-like effects in wild-type but not in TAAR1 knockout mice. These results demonstrate that AlphaFold structures can accelerate drug discovery.
- 9 August 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (32) , eadn1524
Top Cited PapersOpen AccessAlphaFold accelerated discovery of psychotropic agonists targeting the trace amine–associated receptor 1
Artificial intelligence is revolutionizing protein structure prediction, providing unprecedented opportunities for drug design. To assess the potential impact on ligand discovery, we compared virtual screens using protein structures generated by the AlphaFold machine learning method and traditional homology modeling. More than 16 million compounds were docked to models of the trace amine–associated receptor 1 (TAAR1), a G protein–coupled receptor of unknown structure and target for treating neuropsychiatric disorders. Sets of 30 and 32 highly ranked compounds from the AlphaFold and homology model screens, respectively, were experimentally evaluated. Of these, 25 were TAAR1 agonists with potencies ranging from 12 to 0.03 μM. The AlphaFold screen yielded a more than twofold higher hit rate (60%) than the homology model and discovered the most potent agonists. A TAAR1 agonist with a promising selectivity profile and drug-like properties showed physiological and antipsychotic-like effects in wild-type but not in TAAR1 knockout mice. These results demonstrate that AlphaFold structures can accelerate drug discovery.